Adovate


Biopharmaceutical company developing drug candidates that target adenosine receptors. Uses a next-generation adenosine drug discovery platform to design patented small-molecule compounds with optimized physicochemical properties and distribution kinetics to enable target-tissue delivery.

Industries

biotechnology
pharmaceutical
test-and-measurement

Nr. of Employees

small (1-50)

Adovate

1180 Seminole Trail, Ste 495, Charlottesville, VA 22901


Patents

Cyclic amide-containing pyridyl xanthines as A2B antagonists

US-12269828-B2

View Details

Cyclic amide-containing pyridyl xanthines as A2B antagonists

US-11814387-B2

View Details

Products

Adenosine receptor-targeted drug candidates

Discovery-stage small-molecule therapeutic candidates designed to target adenosine receptors with optimized physicochemical properties and distribution kinetics to enhance tissue exposure.

Expertise Areas

  • Adenosine receptor drug discovery
  • Small-molecule medicinal chemistry
  • Physicochemical property optimization
  • Pharmacokinetics and biodistribution optimization
  • Show More (2)

Key Technologies

  • Adenosine receptor targeting
  • Small-molecule design
  • Physicochemical property optimization
  • Pharmacokinetic/biodistribution profiling
  • Show More (1)

News & Updates

The company states its platform enables design of patented compounds with optimized physicochemical characteristics and distribution kinetics.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.